Strategic trade
Trade view / 24 August 2016 at 11:54 GMT

#SaxoStrats: Novo Nordisk looks to win in China

Head of Equity Strategy / Saxo Bank

As mentioned in our morning call Novo Nordisk shares are down 15% since the disappointing Q2 earnings report that contained a cut to forecasts. However, beneath all the data points the China story is growing stronger every quarter. In Q2 it was even more gratifying to see Novo Nordisk gaining market share in China and beating its peers by a wide margin. We believe China and other markets will offset temporary weakness in North America driven by pricing pressures and that investors will buy into the declines acknowledging that Novo Nordisk is still one of the most interesting growth stories in Europe.

In addition, the company has a very robust business model and very high return on capital. The free cash flow yield given high sales growth and robust operating income is very attractive. We are implementing our long Novo Nordisk with a stop loss at 302 and take profit limit at 350.

Novo Nordisk weekly share price the past five years:


Buy: Novo Nordisk B share, NOVOb:xcse

Stop: DKK302

Target: DKK350

Time horizon: strategic

Non-independent investment research disclaimer applies. Read more
24 August
SierraPt. SierraPt.
Peter, many thanks for the idea! Can you please share status of your model portfolio, I.e. Which positions you still recommend holding. Thanks!


The Saxo Bank Group entities each provide execution-only service and access to permitting a person to view and/or use content available on or via the website is not intended to and does not change or expand on this. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on or as a result of the use of the Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. When trading through your contracting Saxo Bank Group entity will be the counterparty to any trading entered into by you. does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of ourtrading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws. Please read our disclaimers:
- Notification on Non-Independent Invetment Research
- Full disclaimer

Check your inbox for a mail from us to fully activate your profile. No mail? Have us re-send your verification mail